As of July 2, 2018 The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) completed the transfer of its major businesses, including its human vaccine business, blood plasma business, and veterinary vaccine business, to KM Biologics Co., Ltd. owned by Meiji Group, Kumamoto business group, and Kumamoto Prefectural Government.


Our contact email:
global-strategy@kmbiologics.com



The Chemo-Sero-Therapeutic Research Institute (Kaketsuken) Product list

KM Biologics Co., Ltd. website:
http://www.kmbiologics.com

General Incorporated Foundation, The Chemo-Sero-Therapeutic Research Institute website:
http://www.kaketsuken.org